The recently published FLAURA trial demonstrated that osimertinib has remarkable efficacy in front-line setting for non-small cell lung cancer (NSCLC). While this has transformed current practice, there are no effective treatments following progression on osimertinib. The aim of our study was to compare progression-free survival (PFS) and overall survival (OS) between patients initiated on osimertinib to those started on other EGFR TKIs.
Methods
This was a multicenter, retrospective study conducted at two large academic centers. Adult patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received EGFR therapy between 2014 and 2019 were included. Patients were dichotomized based on front-line TKI (osimertinib vs. other). PFS, OS, and time-to-discontinuation were evaluated.
Results
One-hundred seventy-two patients were included in the final analysis. Fifty-two (30.2%) patients received osimertinib and 120 (69.8%) patients received another EGFR TKI. The PFS rates at 6, 12, and 18 months were 86.3%, 79.5%, 69.8% in the osimertinib group and 86.6%, 64.2%, 39.3% in the other EGFR TKI group, respectively (p < 0.0036).Estimated OS at 6, 12, and 18 months was similar for both groups: 94.2%, 94.2%, 80.2% and 95.7%, 93.9%, 84.1%, respectively [Adjusted HR = 0.95 (95% CI, 0.37–2.44; p < 0.9128].
Conclusion
Osimertinib demonstrated greater 12 and 18 month PFS compared to other EGFR TKIs. This finding is consistent with results of the FLAURA trial. However, unlike FLAURA, there were no differences in estimated OS between the two groups in our study. Further research to evaluate optimal sequencing strategies in the real world of first, second and third generation TKIs is needed.
SiegelRLMillerKDJemalA.Cancer statistics, 2020. CA A Cancer J Clin2020;
70: 7–30.
2.
FangSWangZ.EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer. Drug Des Devel Ther2014;
8: 1595–1611.
3.
DouillardJYOstorosGCoboM, et al.
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase- IV, open-label, single-arm study. Br J Cancer2014;
110: 55–62. doi:10.1038/bjc.2013.721.
4.
RosellRCarcerenyEGervaisR, et al.
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC).Lancet Oncol2012;
13: 239–246.
5.
SoriaJCOheYVansteenkisteJ, et al.
Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med2018;
378: 113–125.
6.
WuYLChengYZhouX, et al.
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050. ) Lancet Oncol2017;
18: 1454–1466.
7.
MokTSWuY-LThongprasertS, et al.
Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med2009;
361: 947–957.
8.
MokTSWuY-LAhnM-J, et al.
Osimertinib or platinum-pemetrex in EGFR T790M-positive lung cancer. N Engl J Med2017;
376: 629–640.
9.
National Comprehensive Cancer Network, Inc. The NCCN non-small cell lung cancer clinical practice guidelines in oncology (version8.2020), 2020, www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (accessed 20 November 2020).
10.
IchiharaEHottaKNinomiyaK, et al.
Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer. Lung Cancer2019;
132: 54–58.
11.
HarrisPATaylorRThielkeR, et al.
Research electronic data capture (REDCap)-a metadata-drivenmethodology and workflow process for providing translational research informatics support. J Biomed Inform2009;
42: 377–381.
12.
MitsudomiTMoritaSYatabeY, et al.
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol2010;
11: 121–128.
13.
YoshiokaHMitsudomiTMoritaS, et al.
Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring mutations of the epidermal growth factor receptor (EGFR). JCO2014;
32: 8117–8117.
14.
MaemondoMInoueAKobayashiK, et al.
North-East Japan study group, gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med2010;
362: 2380–2388. doi:10.1056/NEJMoa0909530
15.
ZhouCWuYLChenG, et al.
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG- 0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol2011;
12: 735–742.
16.
ZhouCWuYLChenG, et al.
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol2015;
26: 1877–1883.
17.
WuYLZhouCLiamCK, et al.
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol2015;
26: 1883–1889.
18.
WuYZhouCHuCP, et al.
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomized phase 3 trial. Lancet Oncol2014;
15: 213–222.
19.
MokTSChengYZhouX, et al.
Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non–small-cell lung cancer and EGFR- activating mutations. JCO2018;
36: 2244–2250.
20.
RamalingamSS, FLAURA Investigators, VansteenkisteJPlanchardD, et al.
Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC. N Engl J Med2020;
382: 41–50. doi:10.1056/NEJMoa191366256
21.
KobayashiSBoggonTJDayaramT, et al.
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med2005;
352: 786–792. Feb 24doi: 10.1056/NEJMoa044238. PMID: 15728811.
22.
HirshVSinghJ.Optimal sequencing strategies in the treatment of EGFR mutation-positive non-small cell lung cancer: Clinical benefits and cost-effectiveness. Am J Health Syst Pharm2020;
77: 1466–1476. Sep 4doi: 10.1093/ajhp/zxaa197. PMID: 32885829; PMCID: PMC7472210.
23.
HochmairMJMorabitoAHaoD, et al.
Sequential treatment with afatiniband osimertinib in patients with EGFRmutation-positive non-small-cell lungcancer: an observational study. Future Oncol2018;
14: 2861–2874. Novdoi: 10.2217/fon-2018-0711. Epub 2018 Oct 19. PMID: 30336693.
24.
HochmairMJMorabitoAHaoD, et al.
Sequential afatinib and osimertinib in patients with EGFR mutationpositive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol2019;
15: 2905–2914., Sepdoi: 10.2217/fon-2019-0346. Epub 2019 Aug 2. PMID: 31370698.
25.
RemonJMenisJHasanB, et al.
The APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on positive PLasma T790M in EGFR-mutant NSCLC patients. Clin Lung Cancer2017;
18: 583–588.
26.
LeXPuriSNegraoMV, et al.
Landscape of EGFR-Dependent and -Independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-Mutant NSCLC. Clin Cancer Res2018;
24: 6195–6203.
27.
SchoenfeldAJChanJMKubotaD, et al.
Tumor analyses reveal squamous transformation and off-Target alterations as early resistance mechanisms to first-line osimertinib in EGFR-Mutant lung cancer. Clin Cancer Res2020;
26: 2654–2663.
28.
PiotrowskaZIsozakiHLennerzJK, et al.
Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov2018;
8: 1529–1539.
29.
OxnardGRHuYMilehamKF, et al.
Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-Positive lung cancer and acquired resistance to osimertinib. JAMA Oncol2018;
4: 1527–1534.
30.
PapadimitrakopoulouVAWuYLHanJY, et al.
Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol2018;
29: viii741–8.
31.
RamalingamSSChengYZhouC, et al.
Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study. Ann Oncol2018;
29: viii740–8.
32.
Piper-VallilloAJSequistLVPiotrowskaZ.Emerging treatment paradigms for EGFR-Mutant lung cancers progressing on osimertinib: a review. JCO2020;
38: 2926–2936.
33.
OffinMSomwarRRekhtmanN, et al.
Acquired ALK and RET gene fusions as mechanisms of resistance to osimertinib in EGFR-Mutant lung cancers. JCO Precis Oncol2018;
2: 1–00126.
34.
ZhouCZengLZhangY, et al.
Responder of gefitinib plus crizotinib in osimertinib failure EGFR-mutant NSCLC-resistant with newly identified STRN-ALK by next-generation sequencing. J Thorac Oncol2019;
14: e143–e144.
